BIOTEC PHARM NOK : ArcticZymes has been awarded a research grant of MNOK 7.2
04/14/2011 | 04:55pm Biotec Pharmacon subsidiary, ArcticZymes AS, has today received a grant of MNOK 7.2 from the Research Council of Norway for a project with the title "Development of new marine enzymes for research and diagnostics". The total project budget is 14.4 MNOK over 3 years.
The project is a user-driven innovation project in the FUGE-program aiming to establish a stronger product development platform for the development of new enzymes for use in molecular biology applications.
ArcticZymes develops, produces and sells enzymes used in molecular DNA technologies and diagnostics. The market is highly expansive, and the rapid and diversifying technological development creates a strong market demand for new and improved enzymes.
ArcticZymes is involved as commercial partner in several marine bioprospecting activities that form a large source and pipeline for new commercial enzymes from the Arctic marine environment, including being a commercial partner of the Sfi MabCent consortium and the MARZymes projects at the University of Tromsø.
The strengthened pipeline of product candidates through strategic partnerships with MabCent, MARZymes and others makes it necessary to increase product development speed and capacity. The partnership with The University of Tromsø in this project will strengthen the entire product development chain and increase capacity from early stage to final product.
For further information, please contact
managing director Jan Buch Andersen
Tel: +47 467 46 171
e-mail: jba@arcticzymes.com:
mailto:jba@arcticzymes.com
About bioprospecting in ArcticZymes:
The Arctic Ocean and Barents Sea is a habitat with extreme and variable conditions that has led to the evolution of unique organisms adapted to these extreme environmental conditions. The high activity of the cold-adapted/psychrophilic enzymes is often coupled to low thermal stability. The heat-lability provides a useful "off-switch" by which the enzyme can easily be inactivated.
Molecular biology and health diagnostic applications are often multi-step processes that require removal of reagents and enzymes during process flow. Irreversible removal of an enzymatic activity by a simple heat inactivation instead of physical extraction significantly reduce the hands-on time of the reaction, eliminate sample loss and reduce the risk of contamination and/or failure.
About Biotec Pharmacon ASA:
Biotec Pharmacon is a biopharmaceutical company that develops and manufactures new immunomodulatory products and cold adapted marine enzymes. The wholly owned Biotec BetaGlucans AS focuses on new and effective solutions within wound care, cancer therapies and other immune related disease areas, while ArcticZymes AS (96% owned) aspires to become a leading supplier of novel enzymes for diagnostics and genetic research.
This information is subject of the disclosure requirements acc. to §5-12 vphl (Norwegian Securities Trading Act)
This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients.
The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and other applicable laws; and
(ii) they are solely responsible for the content, accuracy and originality of the
information contained therein.
Source: Biotec Pharmacon ASA via Thomson Reuters ONE
HUG#1506769
